Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Giamarellou, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giamarellou, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 229-233
© 2002 The British Society for Antimicrobial Chemotherapy

Leading articles

Prescribing guidelines for severe Pseudomonas infections

Helen Giamarellou,*

Fourth Department of Internal Medicine, Athens University School of Medicine, Sismanoglio General Hospital, 1 Sismanogliou Str., 151 26 Maroussi Attikis, Athens, Greece

Almost 50 years ago, Pseudomonas aeruginosa was rarely considered as a real pathogen. In the 1970s it was recognized as the microorganism associated with bacteraemia in the neutropenic host. Nowadays, it is among the most common pathogens involved in nosocomial infections. Hospital reservoirs of the microorganism include respiratory equipment, antiseptics, soap, sinks, mops, hot tubs, artificial fingernails, and physiotherapy and hydrotherapy pools.1 In addition, the lower respiratory tract of mechanically ventilated patients, the gastrointestinal tract of patients on anticancer chemotherapy, as well as any mucosa and the skin of hospitalized patients treated with broad-spectrum antibiotics, can be colonized with P. aeruginosa at rates exceeding 50%.1 The hands of hospital personnel serve as the bridge between the inanimate and animate environments.2,3

The physician of the new millenium should consider that P. aeruginosa will continue to belong among the major virulent pathogens implicated in the following major syndromes:1,4–6 (i) pneumonia in mechanically . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. P. Zavascki, A. L. Barth, A. L. S. Goncalves, A. L. D. Moro, J. F. Fernandes, A. F. Martins, F. Ramos, and L. Z. Goldani
The influence of metallo-{beta}-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections
J. Antimicrob. Chemother., August 1, 2006; 58(2): 387 - 392.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. P. Crespo, N. Woodford, A. Sinclair, M. E. Kaufmann, J Turton, J. Glover, J. D. Velez, C. R. Castaneda, M. Recalde, and D. M. Livermore
Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-{beta}-Lactamase, in a Tertiary Care Center in Cali, Colombia
J. Clin. Microbiol., November 1, 2004; 42(11): 5094 - 5101.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
L. Pagani, E. Mantengoli, R. Migliavacca, E. Nucleo, S. Pollini, M. Spalla, R. Daturi, E. Romero, and G. M. Rossolini
Multifocal Detection of Multidrug-Resistant Pseudomonas aeruginosa Producing the PER-1 Extended-Spectrum {beta}-Lactamase in Northern Italy
J. Clin. Microbiol., June 1, 2004; 42(6): 2523 - 2529.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. G. Higgins, A. C. Fluit, D. Milatovic, J. Verhoef, and F.-J. Schmitz
Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa
J. Antimicrob. Chemother., August 1, 2002; 50(2): 299 - 301.
[Full Text] [PDF]